Sign In
Last checked at 
7 Feb 2019 11:49
Director Dealings / Market Share Transactions
Oxford, UK - 07 February 2019: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Andrew Heath, Deputy Chairman and Senior Independent Director of the Group, purchased 972 ordinary shares of 50p each ("Ordinary Shares") in the Company on 06 February 2019 on the London Stock Exchange at a price of 715p and sold 981 Ordinary Shares on 06 February 2019 on the London Stock Exchange at a price of 713p in order to transfer the shares into his ISA.
Following this purchase and sale Dr. Andrew Heath holds 43,977 shares representing 0.07% of the Company.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold and purchased.
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Dr. Andrew Heath
| |
2. | Reason for the notification
| ||
a. | Position/status | Deputy Chairman and Senior Independent Director
| |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford BioMedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Oxford BioMedica plc Ordinary Shares of 50p each
GB00BDFBVT43
| |
b. | Nature of the transaction | Purchase of ordinary shares
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
|
| £7.15 | 972 |
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
972
£7.15 £6,949.80
| |
f. | Date of the transaction | 2019-02-06
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Dr. Andrew Heath
| |
2. | Reason for the notification
| ||
a. | Position/status | Deputy Chairman and Senior Independent Director
| |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford BioMedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Oxford BioMedica plc Ordinary Shares of 50p each
GB00BDFBVT43
| |
b. | Nature of the transaction | Disposal of ordinary shares
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
|
| £7.13 | 981 |
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
981
£7.13 £6,994.53
| |
f. | Date of the transaction | 2019-02-06
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
The issued share capital of the Group is 66,122,617 ordinary 50p shares.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: Stuart Paynter, Company Secretary |
Tel: +44 (0)1865 783 000 |
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations and GC LabCell, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at www.oxb.com
Follow the stocks
